Order Article Reprints

Yadav V, House A, Matiz S, McCoubrey LE, Bettano KA, Bhave L, Wang M, Fan P, Zhou S, Woodhouse JD, et al. Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease. Pharmaceutics. 2022; 14(11):2385. https://doi.org/10.3390/pharmaceutics14112385

Yadav, Vipul, Aileen House, Silvia Matiz, Laura E. McCoubrey, Kimberly A. Bettano, Leena Bhave, Meiyao Wang, Peter Fan, Siqun Zhou, Janice D. Woodhouse, and et al. 2022. "Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease" Pharmaceutics 14, no. 11: 2385. https://doi.org/10.3390/pharmaceutics14112385

Yadav, V., House, A., Matiz, S., McCoubrey, L. E., Bettano, K. A., Bhave, L., Wang, M., Fan, P., Zhou, S., Woodhouse, J. D., Poimenidou, E., Dou, L., Basit, A. W., Moy, L. Y., Saklatvala, R., Hegde, L. G., & Yu, H. (2022). Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease. Pharmaceutics, 14(11), 2385. https://doi.org/10.3390/pharmaceutics14112385